Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Finite-Lived Intangible Assets by Year
Finite-Lived Intangible Assets — Net carrying amount ($M) ($M)
Pfizer Finite-Lived Intangible Assets: $31,510M in FY2025, down 12.1% from a year earlier.
Latest, FY2025
31,510
Period ended Dec 31, 2025
Change on a year earlier
-12.1%
35,848 in FY2024
History
11 years
Since FY2015
Sources
11
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Goodwill & Other Intangible Assets Footnote.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Finite-Lived Intangible Assets — Net carrying amount ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 31,510 | -12.1% | Form 10-Q (filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 35,848 | -10.6% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 40,116 | +32.8% | Form 10-K (filed 2025-02-27) ↗ |
| FY2022 | Dec 31, 2022 | 30,215 | +45.9% | Form 10-K (filed 2024-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 20,714 | -12.8% | Form 10-K (filed 2023-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 23,762 | -9.0% | Form 10-K (filed 2022-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 26,117 | -15.9% | Form 10-K (filed 2021-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 31,045 | -15.1% | Form 10-K (filed 2020-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 36,562 | +2.5% | Form 10-K (filed 2019-02-28) ↗ |
| FY2016 | Dec 31, 2016 | 35,664 | +10.9% | Form 10-K (filed 2018-02-22) ↗ |
| FY2015 | Dec 31, 2015 | 32,165 | – | Form 10-K (filed 2017-02-23) ↗ |
Breakdown
What makes up finite-Lived Intangible Assets
- Finite-lived intangible assets — Gross carrying amount ($M)104,006 · FY2025
- Finite-lived intangible assets — Accumulated amortization ($M)72,496 · FY2025
- Developed technology rights — Net carrying amount ($M)30,458 · FY2025
- Brands — Finite-lived net carrying amount ($M)0 · FY2025
- Licensing agreements & other — Net carrying amount ($M)1,052 · FY2025
- Indefinite-Lived Intangible Assets (IPR&D & Brands) — Carrying amount ($M)22,221 · FY2025
- In-Process R&D (IPR&D) — Indefinite-lived carrying amount ($M)21,760 · FY2025
- Estimated future intangible amortization — Year 1 ($M)4,677 · FY2025
- Estimated future intangible amortization — Year 2 ($M)4,087 · FY2025
- Estimated future intangible amortization — Year 3 ($M)3,723 · FY2025
- Estimated future intangible amortization — Year 4 ($M)2,775 · FY2025
- Estimated future intangible amortization — Year 5 ($M)2,732 · FY2025
Cite this data
StockData. (2026). Pfizer Finite-Lived Intangible Assets ($M), annual FY2015–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/intang-net-tot
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.